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Objective. To assess costs, effectiveness, and cost-effectiveness of inhaled corticoste-
roids (ICS) augmenting bronchodilator treatment for chronic obstructive pulmonary
disease (COPD).
Data Sources. Claims between 1997 and 2005 from a large managed care database.
Study Design. Individual-level, fixed-effects regression models estimated the effects of
initiating ICS on medical expenses and likelihood of severe exacerbation. Bootstrap-
ping provided estimates of the incremental cost per severe exacerbation avoided.
Data Extraction Methods. COPD patients aged 40 or older with  15 months of
continuous eligibility were identified. Monthly observations for 1 year before and up to
2 years following initiation of bronchodilators were constructed.
Principal Findings. ICS treatment reduced monthly risk of severe exacerbation by
25 percent. Total costs with ICS increased for 16 months, but declined thereafter. ICS
use was cost saving 46 percent of the time, with an incremental cost-effectiveness ratio of
$2,973 per exacerbation avoided; for patients  50 years old, ICS was cost saving 57
percent of time.
Conclusions. ICS treatment reduces exacerbations, with an increase in total costs
initially for the full sample. Compared with younger patients with COPD, patients aged
50 or older have reduced costs and improved outcomes. The estimated cost per severe
exacerbation avoided, however, may be high for either group because of uncertainty as
reflected by the large standard errors of the parameter estimates.
Key Words. Chronic obstructive pulmonary disease, managed care, administrative
data, cost-effectiveness analysis
Chronic obstructive pulmonary disease (COPD) is characterized by progres-
sive airflow limitation and airway inflammation leading to a gradual loss in
lung function (Global Initiative for Chronic Obstructive Lung Disease
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[GOLD] 2006). Acute exacerbations (i.e., sudden worsening of respiratory
symptoms) are common for many COPD patients and are most often caused
by respiratory tract infections (White, Gompertz, and Stockley 2003). These
exacerbations are an important part of the morbidity, mortality, and disease
progression. Patients with lower levels of lung function are more likely to
experience more exacerbations, and frequent exacerbations may lead to
reduced lung function (Seemungal et al. 2000; Calverley et al. 2005). Exac-
erbations are strongly related to increases in health care utilization, including
inpatient admissions, emergency department visits, and use of rescue med-
ications (Donaldson and Wedzicha 2006).
Because airway inflammation is one aspect of COPD, anti-inflammatory
agents such as inhaled corticosteroids (ICS) may slow disease progression and
prevent exacerbations. Current treatment guidelines recommend a stepwise
increase in drug treatment depending on the disease severity (GOLD 2006).
In particular, ICS treatment should be used to augment regular bronchodi-
lator treatment for patients with advanced disease and repeated exacerbations.
However, unlike the use of ICS in asthma treatment, the evidence for ICS
efficacy is mixed for COPD treatment (Calverley 2004). In six randomized
clinical studies in which COPD patients were followed for more than
12 months, ICS treatment was associated with a 4–26 percent reduction in
exacerbation events defined by either respiratory-related hospitalizations,
emergency department visits, worsening of respiratory symptoms, or their
combination (Vestbo et al. 1999; Burge et al. 2000; Lung Health Study Re-
search Group [LHSRG] 2000; Szafranski et al. 2003; Calverley, Pauwels et al.
2003; Calverley, Boonsawat et al. 2003). The most recent randomized clinical
study (TORCH study) showed that the combination therapy of ICS and an
inhaled bronchodilator reduced the risks of dying ( p 5 .052) and of moderate
and severe exacerbations ( po.001) during the 3-year follow-up (Calverley
et al. 2007).
Because severe exacerbations are uncommon in COPD patients, large
studies with adequate follow-up periods are required to detect statistically and
clinically significant effects of drug treatments. Pooled analyses using more
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than 4,000 COPD patients from randomized clinical trials of ICS showed that
ICS reduced exacerbation rates by 24–33 percent compared with a placebo
(Sin et al. 2003; Gartlehner et al. 2006). On the other hand, observational
studies using more than 4,000 COPD patients find no preventive effects as-
sociated with ICS (Bourbeau et al. 2003; Fan et al. 2003; de Melo, Ernst, and
Suissa 2004; Suissa 2004) even though potential misclassification of ICS
exposure status was carefully addressed by using either a time-dependent
approach or a nested case–control study design.
One possible explanation for these mixed results may be the lack of a
consistent definition of exacerbation. Because substantial individual variation
occurs in exacerbation patterns, exacerbation episodes are operationally
defined in various ways across studies, ranging from ‘‘mild exacerbation’’
defined by increased use of rescue therapy to ‘‘severe exacerbation’’ defined
by respiratory conditions that require hospitalization (Calverley 2004;
Pauwels et al. 2004). Other reasons for these mixed results may be related
to individual factors that are not observed in claims data but that influence
disease prognosis. Important unobserved characteristics that could bias the
previous estimations include socioeconomic characteristics, smoking behav-
ior, and chronic comorbid conditions (Burney et al. 2003; Spencer et al. 2004;
Mannino et al. 2006).
In cross-sectional data analysis, omission of important factors from the
regression model will lead to biased estimation. However, in longitudinal or
panel data analysis, an individual has multiple observations of both exposure
status and outcomes (Frees 2004). Each individual contributes time before
drug exposure to the control group and time after drug exposure to the treat-
ment group. Because each individual is his or her own control, potential bias
due to person-specific omitted variables that do not change over time (e.g.,
education, historical health behaviors, and underlying health status) can be
eliminated. With at least two observations per person, the treatment effect can
be observed by measuring changes before and after the treatment (e.g., as a
pre- and post-paired comparison), and thus time-invariant variables disappear
by subtracting one from the other.
One statistical approach to account for multiple observations per indi-
vidual is called the ‘‘fixed-effects’’ model (Allison 2005). The model can be
expressed as:
Y it ¼ bXit þ ai þ gWit þ eit ð1Þ
The notation i refers to different persons and t refers to different points in time;
the term Yit is an outcome of interest, Xit is a main exposure of interest, ai is a
2166 HSR: Health Services Research 43:6 (December 2008)
dummy variable representing individual characteristics; Wit is a vector of
time-variant variables of interest; and eit is a random error. In this model,
because individual variations are considered fixed and are captured by the
fixed-effect parameter, ai , omitted time-invariant variables are accounted for
without measuring them. Wit, factors that change over time (e.g., disease
symptoms) must be adjusted with common regression approaches, and
unobserved time-varying factors may still cause bias.
In previous observational studies using claims data, limited information
was available to measure and adjust for the effects of important predictors of
prognosis of COPD, such as smoking history or chronic conditions (Sin and
Tu 2001; Bourbeau et al. 2003; Suissa 2004). In this study, however, we ad-
dress the potential bias that is likely to exist in the cross-sectional studies
by using monthly data from a managed care claims database to obtain re-
peated measures over time for each individual. We use an individual-level,
fixed-effects model to estimate the unbiased effects of adding ICS treatment on
monthly medical expenses and likelihood of severe exacerbations among
COPD patients who were initially under treatment with regular bronchodi-
lators. We use parameter estimates from these two models to determine the
incremental cost per severe exacerbation avoided.
METHODS
Data Source
Study data were obtained from the National Managed Care Benchmark Da-
tabase (Integrated Healthcare Information Services [IHCIS], Waltham, MA)
from January 1997 through December 2005. This database includes infor-
mation on enrollment, facility, professional, and pharmacy services for more
than 37 million patients covered by approximately 35 managed care health
plans in nine census regions in the United States. For patients of Medicare age,
the IHCIS dataset was able to capture pharmacy claims through health plan-
sponsored Medicare programs that included pharmacy benefits. All data were
HIPAA-compliant, with all health plan and personal information de-identified
to assure confidentiality. IRB approval for the human subjects research was
obtained from the Office of Human Research Ethics of the University of North
Carolina at Chapel Hill.
IHCIS costs are provided in a standardized form in order to make
comparisons easier across all services, data sources, and time periods. IHCIS
uses different approaches to standardize pricing for each of the following
major service categories: (1) facility inpatient costs are calculated based on
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primary diagnosis categories, length of stay, and presence of intensive care
unit use/surgery; (2) facility outpatient costs are calculated based on requested
(submitted) charges; (3) professional service costs are calculated using a stan-
dardized payment schedule based on a resource-based relative value scale;
and (4) pharmacy service costs, including ICS costs, are calculated using First
Data Bank pricing based on the National Drug Code and quantity of the
prescription (IHCIS 2005). In order to reflect allowed payments among all
service providers, deductibles, coinsurance, and other cost-sharing features
are removed from the original data. All costs are adjusted to 2005 U.S. dollars
using the Consumer Price Index for Medical Care Services.
Study Population
COPD patients were identified using both medical and pharmacy claims.
Patients were included if they (1) had one or more medical claims of COPD
(International Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM): 491.xx, 492.xx or 496.xx in primary or secondary positions)
between January 1998 and December 2004, (2) had regular treatment with
inhaled bronchodilators (defined by at least three pharmacy claims of anti-
cholinergics or long-acting b2-agonists), and (3) were aged 40 or older. All
eligible patients were required to have continuous health plan coverage in-
cluding pharmacy benefits from 3 months before the first pharmacy claim
of inhaled bronchodilators through 12 months after the date of that claim.
Patients were excluded from the analysis if they had a diagnosis of cystic
fibrosis (ICD-9-CM: 277.0x) or respiratory tract cancer (ICD-9-CM: 160.xx-
164.xx, or 231.xx), no ICS treatment during the follow-up period, or initiated
ICS before the first bronchodilator treatment. To investigate whether effects of
ICS varied by age, we also conducted all analyses for patients aged 50 and
older.
Measures
Monthly observations were created for ICS treatment status, medical ex-
penses, likelihood of a severe exacerbation event, and other explanatory
variables from up to 12 months before the first bronchodilator claim through
24 months after that claim. The medical expenses were identified from in-
patient, outpatient, and pharmacy claims (including ICS treatment expenses).
Severe exacerbation events were identified by inpatient or emergency
department claims, with primary diagnosis of COPD or with COPD-related
procedures (e.g., oxygen therapy, a spirometry test, pulmonary rehabilitation,
nebulized treatment, bronchoscopy, intubation, or tracheostomy).
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The main exposure variable was the use of ICS. The period before the
first ICS claim was defined as unexposed time, whereas the period after the
first ICS claim was defined as ICS treatment time. To adjust for symptom
changes over time, a continuous variable indicating ‘‘time’’ in months (coded
from  12 to 23, with month 0 designating the initiation of bronchodilator
treatment), dummy variables indicating ‘‘onset’’ (1 month before the first
bronchodilator claim when many patients received medical services that led
to the initiation of bronchodilator treatment, and therefore had extremely high
medical costs), and ‘‘post onset’’ (months after patients receive the broncho-
dilator treatment) were included.
Covariates were age and selected comorbid conditions such as asthma
and congestive heart failure. For patients with asthma or congestive heart
failure, we defined time with the conditions in the following way: we identified
the first month with an asthma claim (ICD-9-CM: 493.xx) or congestive heart
failure claim (ICD-9-CM: 428.xx) and then defined the subsequent months as
months with the conditions. In addition, to adjust for exacerbation episodes,
the months with medications for acute exacerbations (i.e., antibiotics or oral
corticosteroids) were identified. Proximity to death could not be controlled
due to lack of mortality information in the database.
Analysis
An individual-level, fixed-effects linear regression model was used to estimate
the impact of initiating ICS treatment on medical expenses and the likelihood
of severe exacerbation among COPD patients. The models were:
E ½costsit  ¼b1timet þ b2onsetit þ b3post onsetit þ b4ICSit þ b5timet  ICSit
þ b6ðtimet  post onsetit  timet  ICSitÞ þ d1ANTit þ d2OCSit
þ d3ASMit þ d4CHFit þ d5MONTHt ð2Þ
Pr½exacerbationit  ¼a1timet þ a2onsetit þ a3post onsetit þ a4ICSit þ g1ANTit
þ g2OCSit þ g3ASMit þ g4CHFit þ g5MONTHt ð3Þ
where time is a continuous variable indicating the number of months from the
first bronchodilator treatment, onset is a dummy variable indicating 1 month
before the first bronchodilator treatment, post onset is a dummy variable in-
dicating months after patients received the first bronchodilator treatment, ICS
is a dummy variable indicating ICS use, ANT and OCS indicate use of rescue
medications (i.e., antibiotics and oral corticosteroids, respectively),
and ASM and CHF indicate having comorbid conditions (i.e., asthma and
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congestive heart failure, respectively). Costs were measured in dollars, and a
dichotomous indicator was used to indicate the occurrence of a severe ex-
acerbation in each month. The model for costs allowed the effect of ICS to
vary with time; the effect of ICS on severe exacerbations did not vary with
time so an interaction of time with ICS treatment was not included in the
exacerbations model. A Hausman specification test was used to assess whether
the fixed-effects model was preferred to a random-effects model (Kennedy
2003).
The interpretation of estimated coefficients from the cost model (Equa-
tion 2) is summarized in Figure 1. The coefficient b1 describes the impact of
natural disease progression on medical expenses. The coefficient b2 accounts
for a change in expenses in the month before the first bronchodilator treat-
ment. Changes in monthly expenses after the first bronchodilator treatment
are expressed by b11b31b6  time; changes after the first ICS treatment are
expressed by b11b31b41b5  time. Thus, the ICS treatment effect on
monthly expenses is expressed by differences in the equations before and
after the first ICS treatment, b41(b5–b6)  time. If adding ICS treatment in-
creases average monthly costs (at least initially), then b4 would be positive (as
shown in Figure 1). If monthly costs increase more slowly with ICS than
without ICS, then the line representing the increase in expected costs with









from adding ICS treatment
are equal to zero
Figure 1: Graphical Representation of Estimated Coefficients from
Fixed-Effects Models
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Figure 1. Thus, the area expressed by the difference in the two equations
(shaded in gray) represents additional medical expenses associated with add-
ing ICS treatment. The lines cross at the point where the estimated additional
monthly expenses are equal to zero and total expenses due to ICS initiation
decrease in subsequent months. If b4 is negative, then adding ICS treatment
results in reduced costs in each month (i.e., the line b11b31b41b5  time will
be below the line b11b31b6  time everywhere).
The parameter estimates from the regressions were used to estimate the
effect of initiating ICS on monthly medical expenses and the likelihood of
avoiding a severe exacerbation event during the months following ICS ini-
tiation. Nonparametric bootstrapping, with repeated samples of 1,000 (Efron
and Tibshirani 1993), was conducted to estimate the likelihood that ICS
treatment is cost saving and to characterize the likelihood that ICS treatment is
cost effective relative to different thresholds of what a decision maker might be
willing to pay for a gain in health outcomes. Results of the bootstrapping
process are displayed in a cost-effectiveness acceptability curve (Van Hout
et al. 1994; Briggs 2000; Briggs, Sculpher, and Claxton 2006). This curve
displays the likelihood or probability that adopting a new technology (in this
case, simultaneous prescribing of ICS with bronchodilators) is the correct
decision (Drummond et al. 2005).
Specifically, we bootstrapped the incremental cost-effectiveness ratio
(ICER), which provides an estimate of the additional cost per severe exac-
erbation avoided. The ICER can be interpreted as the monetary value of
avoiding a severe exacerbation beyond the medical costs directly involved in
treatment (i.e., what one might be willing to pay to avoid the psychological
trauma and indirect costs to the individual and family members of a severe
exacerbation). Bootstrapping the model accounts for the correlation between
the numerator (i.e., expected costs from Equation 2) and the denominator
(i.e., risk of exacerbation from Equation 3) (Chaudhary and Stearns 1996). All
analyses were conducted using STATA version 9.2 (StataCorp LP, College
Station, TX).
RESULTS
We identified 785,759 COPD patients without diagnoses of cystic fibrosis or
respiratory tract cancer in the IHCIS database between 1998 and 2004.
Reductions in the sample occurred because of the lack of at least 15 months of
data (n 5 473,691), lack of pharmacy benefit coverage (n 5 234,411), lack of
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required medication regimens (n 5 54,340), or patient age younger than
40 years (n 5 4,748). A total of 10,271 eligible patients met all inclusion and
exclusion criteria.
Patient demographics, comorbid conditions, prior utilization (during
3 months before initiating bronchodilator treatment), and post-term treat-
ments (during 24 months after initiating bronchodilator treatment) are sum-
marized in Table 1. Approximately half of the study sample was male; 85
percent of patients were aged 50 and older, whereas 53 percent were aged 60
and older. Approximately 20 percent of patients received services from a
pulmonary medicine specialist and a spirometry test during the 3 months
before initiating bronchodilator treatment. Patients had a variety of comorbid
conditions, including hypertension (37 percent), asthma (37 percent), diabetes
(14 percent), congestive heart failure (12 percent), and depression (12 percent).
In terms of resource utilization, fewer than 20 percent of patients used either
respiratory-related inpatient services or emergency department visits. Patients
aged 50 and older were similar in their use of resources and the presence of
comorbid conditions.
In this analysis, we used follow-up data for up to 24 months after ini-
tiating bronchodilator treatment. Sixty-one percent of patients had complete
24-month follow-up data, and the mean duration of the follow-up was
21.2 months (standard deviation [SD], 3.9 months). Patients used ICS for
16.6 months (SD, 7.0 months) on average, with an average of 5.8 ICS pre-
scriptions costing $150 per prescription. Unadjusted mean ICS expenses per
person per month were $53.62 (SD, $50.42). Unadjusted outcomes also are
summarized in Table 1. COPD patients (in the full sample) incurred medical
expenses of $1,131 (SD, $2,037) per month (excluding pharmacy expenses)
and pharmacy expenses of $323 (SD, $309) per month, respectively. The
likelihood of having a severe exacerbation per month was 0.0140 (SD, 0.0386).
Although total medical expenses (exclusive of pharmacy expenses) were
slightly higher for older COPD patients, pharmacy expenses and the likeli-
hood of exacerbation were similar.
The effects of ICS treatment on the monthly medical expenses and
likelihood of severe exacerbation for the full sample (40–79 years old) and the
older patient group (ages 50–79 years old) are summarized in Table 2. For the
full sample, ICS treatment was associated with increased medical expenses
during the first month even though the amount ($23.08, the coefficient b4) was
not statistically significant at the 5 percent level. The expected additional
monthly expenses, expressed by b41(b5 –b6)  time 5 23.08–1.37  time,
decreased over time, with total costs expected to decrease beyond month
2172 HSR: Health Services Research 43:6 (December 2008)
Table 1: Summary Statistics for Full Sample (n 5 10,271) and Persons Aged
50 and Older (n 5 8,738)
Variables
Mean (SD)
Full Sample Age 50 and Older
Outcomes






Pharmacy expenses per month $323.16 ($309.07) $323.71 ($291.23)
Likelihood of having severe exacerbation event per
month
0.0140 (0.0386) 0.0150 (0.0401)
Demographics
Gender: male 0.4596 0.4754
Age 40–49 years 0.1493 ——
Age 50–59 years 0.3246 0.3816
Age 60–69 years 0.2871 0.3375
Age 70–79 years 0.2390 0.2810
Insurance: Medicaid/Medicare (ref: any other) 0.1532 0.1737
Census region: Northeast 0.5174 0.5113
Census region: South 0.1216 0.1217
Census region: Midwest 0.1119 0.1181
Census region: West/others 0.2491 0.2489
Comorbid conditions (during 3 months before and after initiating bronchodilator treatment)
Myocardial infarction 0.0363 0.0399
Congestive heart failure 0.1243 0.1402
Peripheral vascular disease 0.0430 0.0480
Cerebrovascular disease 0.0570 0.0643
Rheumatologic disease 0.0230 0.0236
Diabetes 0.1435 0.1551




Nonvertebral fracture 0.0326 0.0346
Hypertension 0.3746 0.3992
Prior utilization (during 3 months before initiating bronchodilator treatment)
Pulmonologist care 0.1952 0.1999
Inpatient admission for any reason 0.1920 0.2000
Inpatient admissions for respiratory-related
conditions
0.1173 0.1198
Emergency department visit for any reason 0.2136 0.2119
Emergency department visits for respiratory-related
conditions
0.1332 0.1310
Oxygen therapy 0.0815 0.0871
Spirometry test 0.1939 0.1928
Pulmonary rehabilitation 0.0216 0.0198
Nebulized therapy 0.0270 0.0271
continued
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16. ICS treatment reduced severe exacerbation risks significantly ( po.001).
The estimated likelihood of having a severe exacerbation event with ICS
treatment was 1.12 percent per month whereas the likelihood without ICS
treatment was 1.49 percent per month, which translated into a 0.37-percent-
age-point absolute risk reduction (1.12–1.49 5  0.37) or a 25-percent relative
risk reduction (1.12/1.49 5 0.75).
For patients aged 50 or older, ICS treatment was associated with a sta-
tistically nonsignificant reduction in total medical expenses during the first
month of ICS treatment ( $4.78, the coefficient b4). Expected monthly
expenses decreased further with time, expressed by b41(b5–b6)  time 5
 4.78–0.15  time. In Figure 1, the line representing costs with ICS treatment
would therefore lie below the line representing costs without ICS treatments.
The statistically significant decrease in the estimated monthly likelihood of a
severe exacerbation was similar to the effect for the full sample.
Although the reductions in monthly costs are modest and take some time
to occur for the full sample, the larger standard errors associated with param-
eter estimates (i.e., costs and the likelihood of a severe exacerbation) and the
implications for the cost effectiveness of ICS treatment are best understood by




Full Sample Age 50 and Older
Bronchoscopy, intubation, or tracheostomy 0.0124 0.0129
Antibiotics 0.3356 0.3222
Oral corticosteroids 0.1708 0.1638
Short-acting b2 agonists 0.2183 0.2082
Theophylline 0.0471 0.0500
Post-term treatments (during 24 months after initiating bronchodilator treatment)
Follow-up time after initiating bronchodilator
treatment (in months)
21.2 (3.9) 21.1 (3.9)
Follow-up time with ICS treatment (in months) 16.6 (7.0) 16.4 (7.0)
ICS costs per month $53.62 (50.42) $54.76 ($51.17)
Number of ICS prescriptions during follow-up 5.8 (5.2) 5.8 (5.2)
ICS costs per prescription $150.35 ($96.06) $153.05 ($99.47)
Days of supply per ICS prescription 34.8n (21.1) 35.6w (21.8)
n287 have missing data.
w239 have missing data.
AIDS, acquired immunodeficiency syndrome; ICS, inhaled corticosteroids; SD, standard
deviation.
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Table 2: Effects of Inhaled Corticosteroids (ICS) Treatment on Monthly
Medical Costs and Monthly Likelihood of Severe Exacerbation
Medical Costs Severe Exacerbation
Coefficient SE Coefficient SE
Ages 40–79 (n 5 10,271)
b1 (follow-up months, time) 44.17 5.90nn 0.00007 0.00004
b2 (1 month before the first
bronchodilator claim, onset )
1251.17 61.45nn 0.05112 0.00115nn
b3 (months after the first bronchodilator
claim, post onset )
 210.08 56.97nn 0.00292 0.00082nn
b4 (months after the first inhaled
corticosteroid claim, ICS )
23.08 50.41  0.00370 0.00078nn
b5 (time  ICS )  53.55 6.20nn
b6 (time  post onset–time  ICS )  52.18 7.92nn
b5b6  1.37 5.59
d1 (month with an antibiotic prescription) 877.67 29.64nn 0.02518 0.00062nn
d2 (month with an oral corticosteroid
prescription)
824.86 39.21nn 0.06330 0.00082nn
d3 (months after the first asthma
diagnosis)
452.95 36.42nn 0.00327 0.00076nn
d4 (months after the first congestive hart
failure diagnosis)
1943.67 51.81nn 0.01731 0.00109nn
Ages 50–79 (n 5 8,738)
b1 (follow-up months, time) 49.15 6.62nn 0.00008 0.00004n
b2 (1 month before the first
bronchodilator claim, onset )
1329.56 68.95nn 0.05465 0.00129nn
b3 (months after the first bronchodilator
claim, post onset )
 238.60 63.74nn 0.00270 0.00091nn
b4 (months after the first inhaled
corticosteroid claim, ICS )
 4.78 56.44  0.00377 0.00088nn
b5 (time  ICS )  58.22 6.97nn
b6 (time  post onset–time  ICS )  58.06 8.89nn
b5b6  0.15 6.26
d1 (month with an antibiotic prescription) 914.94 33.73nn 0.02778 0.00071nn
d2 (month with an oral corticosteroid
prescription)
798.38 44.47nn 0.06803 0.00093nn
d3 (months after the first asthma
diagnosis)
483.88 41.66nn 0.00355 0.00087nn
d4 (months after the first congestive heart
failure diagnosis)
1963.58 55.61nn 0.01782 0.00117nn
nStatistical significance at the 5% level;
nnStatistical significance at the at the 1% level.
A Hausman specification test confirmed that the fixed-effects model was appropriate.
b, estimated coefficients; SE, robust standard errors.
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estimates from the regression results. This analysis calculates the empirical
distribution of the ICER, which estimates the additional cost per severe ex-
acerbation avoided. Because total costs increased through 16 months follow-
ing the initiation of ICS treatment for the full sample (i.e., because the estimate
of b4 was positive), we calculated the cost-effectiveness implications for the full
sample for 17 months following initiation of ICS treatment. More specifically,
we calculated the increase in costs as the shaded area in Figure 1 for the
numerator of the ICER and used the cumulative reduction in the likelihood of
avoiding an exacerbation event (assuming independence between months)
as the denominator. In addition, we conducted the same analysis for the
subgroup ages 50 and older to compare the results. The estimates, therefore,
represent the maximum cost to avoid a severe exacerbation for 17 months
after ICS initiation (because total costs are expected to decrease 17 months
after ICS initiation for the full sample).
Figure 2 summarizes the results from the analysis. Incremental medical
expenses were calculated as the sum of additional monthly expenses from the
ICS treatment for 17 months following initiation (mean, $190.34 and SD,
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Full Sample Persons Ages 50–79
Figure 2: Cost-Effectiveness Acceptability Curve for Inhaled Corticosteroids
(ICS) Treatment to Prevent Severe Exacerbation Events, Based on 17 Months
of Follow-Up
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aged 50 and older). Incremental effectiveness was calculated as the sum of
monthly risk reductions of having a severe exacerbation event (mean, 0.0982
and SD, 0.0252 for the full sample; mean, 0.0965 and SD, 0.0277 for the group
aged 50 and older). For the full sample, the likelihood that ICS treatment is
cost saving is 45.5 percent. The ICER was $2,973 per severe exacerbation
avoided. The cost to avoid a severe exacerbation with a high degree of
certainty is substantial. For example, at a cost of $30,000 to avoid an acute
exacerbation, the likelihood that ICS treatment is cost effective is about 96
percent. The likelihood that ICS treatment is cost saving is higher for the older
sample, at approximately 56.7 percent, indicating that on average ICS treat-
ment in persons aged 50 and older reduces total costs and improves outcomes;
however, the threshold for cost effectiveness becomes similar to that for the
full sample (about $30,000 with 95 percent confidence).
DISCUSSION
Our findings using longitudinal data demonstrate that adding ICS treatment to
regular inhaled bronchodilators for patients with COPD most likely increases
total medical expenses initially, although severe exacerbation risks decline
and total costs eventually decline. The likelihood of reductions in both costs
and exacerbations is greater for older patients, although the cost per avoided
severe exacerbation may still be high. Yet when one considers unmeasured
consequences of repeated exacerbations (i.e., decreased quality of life, pro-
ductivity loss, or caregiver time), the additional expenses may be compensated
by additional benefits (D’Souza et al. 2006; Simoens and Decramer 2007).
It is difficult to compare our estimates of the additional expenses to avoid
a severe exacerbation with those from prior studies. Ayres, Price, and
Efthimiou (2003) used data from a randomized, controlled trial to assess the
cost effectiveness of adding ICS in the form of fluticasone propionate to
regular bronchodilator therapy in symptomatic patients with moderate-to-
severe COPD. Their estimate from the United Kingdom’s National Health
Service perspective was d7.5 per month (approximately $11) to have a
moderate/severe exacerbation-free day. Sin, Golmohammadi, and Jacobs
(2004) reported an estimate of $10,000 per moderate and severe exacerbation
avoided in a 3-year Markov model. Yet the groups analyzed by these studies
were substantially sicker (having a monthly rate of exacerbations of 15
percent, compared to 1.4 percent in our study) and the focus of those
calculations was not on the incremental cost of early initiation of ICS.
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Several important limitations associated with claims data deserve dis-
cussion (Schneeweiss and Avorn 2005). Because no clinical information about
COPD or other comorbid conditions were available, we estimated severity of
COPD from resource utilization patterns in the claims data. Severe exacer-
bation events were identified using COPD-related hospital admissions or
emergency department visits, which often are used to relieve severe exacer-
bations (Ayres, Price, and Efthimiou 2003; Sin, Golmohammadi, and Jacobs
2004). Comorbid conditions were identified with the first medical claim as-
sociated with the comorbidity diagnosis, and we assumed that the conditions
would continue until the end of the study period. These proxy measures could
cause bias due to the misclassification of explanatory variables. However, this
type of measurement error should be random (i.e., not associated with drug
selection or outcomes) and will result in bias toward the null (i.e., no difference
between the groups).
In addition, we did not have access to data that might explain the reason
for initiating ICS treatment. We assume some physicians may prescribe ICS to
prevent exacerbations, whereas others may prescribe it only to patients having
frequent exacerbations (Collet and Boivin 2000). Without clinical information,
it was difficult to distinguish whether estimated expenses were the result of the
treatment or whether ICS treatment was initiated due to the expected out-
comes. To minimize the bias from this temporal causal relationship, we used a
narrow time frame to measure both drug exposure status and outcomes and
used monthly values in the analysis. Also, we included month indicator vari-
ables to adjust for seasonality. If patients used ICS because they experienced
frequent exacerbations, ICS should be associated with increased medical ex-
penses. We believe, therefore, that the direction of the bias would be one way
only: ICS treatment effects on medical expenses and exacerbation risks would
be underestimated and our estimated benefits would be conservative.
Finally, to identify an appropriate study sample, we used various inclu-
sion and exclusion criteria such as diagnosis codes, COPD-related medica-
tions (at least three bronchodilator prescriptions with an interquartile range of
2.3–9.6 months), and patient age (40 years or older). To assess impact of
changes in ICS treatment status over time, all patients were required to have at
least 15 months of continuous eligibility; failure to meet this criteria was the
main cause for exclusion from the original study population. As a consequence
of this restriction, patients who did not survive and continue enrollment for at
least 15 months were automatically excluded. Therefore, the findings from
this study are only generalizable to COPD patients from a managed care
population who survive and continue to be covered by that managed care
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organization, including pharmacy benefits for at least 15 months after initi-
ation of bronchodilator treatment.
CONCLUSIONS
Current clinical guidelines recommend that ICS treatment should be initiated
in patients who do not have adequate symptom control using a regular
bronchodilator regimen. Our findings provide additional information that
may support early initiation of ICS, especially in older patients. Increased
medical expenses due to regular ICS treatment are anticipated initially for
patients on average. However, these expenses may be compensated by
additional health benefits from avoiding repeated exacerbations and by
preventing disease progression in long-term disease management. Although
patients were only followed for up to 2 years following initiation of broncho-
dilator treatment, the analyses suggest that initiation of ICS treatment
eventually leads to reductions in total costs for longer-surviving patients.
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